Preclinical Oncology Services Ltd (Precos) has signed its first deal since being spun out from Nottingham University in August, with Janssen Pharmaceutica. The work will support Janssen’s oncology drug discovery, development and biomarker programmes.
The agreement is a consolidation of the working relationship between the two companies that began when Precos was working within the university.
Sue Watson, Chief Scientific Officer of Precos, said this deal, “Consolidates Precos’ evolution from a primarily academic background into an ambitious commercial entity, offering significant scientific expertise and delivering highly specialist services in the development of new anti-cancer drugs.”
Martin Page, Vice President, Head of Global Oncology Research, Janssen Research & Development, said, “Our agreement with Precos is a natural extension of our long-standing relationship with the University of Nottingham; we look forward to continuing to build on our past successes.”